Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Supportive care in marrow transplantation.

W I Bensinger1

  • 1Fred Hutchinson Cancer Research Center, Seattle, Washington.

Current Opinion in Oncology
|August 1, 1992
PubMed
Summary

Marrow transplantation is a vital therapy for various diseases. Supportive care and targeted interventions significantly reduce treatment toxicities and improve patient outcomes after transplantation.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Bendamustine, etoposide and dexamethasone to mobilize peripheral blood hematopoietic stem cells for autologous transplantation in patients with multiple myeloma.

Bone marrow transplantation·2016
Same author

A phase 2 study of bortezomib, cyclophosphamide, pegylated liposomal doxorubicin and dexamethasone for newly diagnosed multiple myeloma.

Blood cancer journal·2016
Same author

A randomized study of melphalan 200 mg/m(2) vs 280 mg/m(2) as a preparative regimen for patients with multiple myeloma undergoing auto-SCT.

Bone marrow transplantation·2015
Same author

Maintenance rituximab after autologous stem cell transplantation in patients with mantle cell lymphoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2015
Same author

Utilization of stored autologous PBSCs to support second autologous transplantation in multiple myeloma patients in the era of novel agent therapy.

Bone marrow transplantation·2015
Same author

Immune escape from NY-ESO-1-specific T-cell therapy via loss of heterozygosity in the MHC.

Gene therapy·2014

Area of Science:

  • Hematology
  • Oncology
  • Immunology

Background:

  • Marrow transplantation is an established therapy for aplastic anemia, genetic disorders, and malignancies.
  • Conditioning regimens involving chemotherapy and radiotherapy are essential for cancer eradication and marrow engraftment.
  • Patients undergoing transplantation experience profound marrow aplasia, immunosuppression, and significant non-marrow toxicities.

Purpose of the Study:

  • To review supportive care strategies and novel interventions to mitigate non-marrow toxicities associated with marrow transplantation.
  • To highlight advancements in managing complications such as infections and organ toxicities.
  • To discuss the role of recombinant growth factors in reducing post-transplant morbidity.

Main Methods:

  • Review of current supportive care practices in marrow transplantation.
  • Analysis of emerging therapeutic strategies targeting non-marrow toxicities.
  • Evaluation of prophylactic measures against infections and organ damage.

Main Results:

  • Intensive supportive care, including nutritional support, transfusions, and antimicrobial prophylaxis, is crucial.
  • Targeted therapies, such as anti-tumor necrosis factor-alpha agents, show promise in reducing conditioning regimen toxicities.
  • Advanced prophylactic strategies for cytomegalovirus infections and the use of recombinant growth factors are improving patient outcomes.

Conclusions:

  • Comprehensive supportive care is indispensable for managing patients undergoing marrow transplantation.
  • Novel pharmacological and biological interventions are critical for reducing treatment-related morbidity and mortality.
  • Continued research into mitigating non-marrow toxicities will further enhance the efficacy and safety of marrow transplantation.

Related Experiment Videos